Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. [electronic resource]
Producer: 20110404Description: 6169-76 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Algorithms
- Antineoplastic Agents, Alkylating -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Aryl Hydrocarbon Hydroxylases -- genetics
- Breast Neoplasms -- drug therapy
- Carcinoma -- drug therapy
- Cyclophosphamide -- adverse effects
- Cytochrome P-450 CYP2B6
- Cytochrome P-450 CYP3A -- genetics
- Disease-Free Survival
- Female
- Glutathione S-Transferase pi -- genetics
- Glutathione Transferase -- genetics
- Humans
- Inactivation, Metabolic -- genetics
- Metabolic Networks and Pathways -- genetics
- Middle Aged
- North America
- Oxidoreductases, N-Demethylating -- genetics
- Polymorphism, Genetic -- physiology
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.